Pharsight

Daliresp is owned by Astrazeneca.

Daliresp contains Roflumilast.

Daliresp has a total of 5 drug patents out of which 2 drug patents have expired.

Expired drug patents of Daliresp are:

US8431154
US9468598

Daliresp was authorised for market use on 28 February, 2011.

Daliresp is available in tablet;oral dosage forms.

Daliresp can be used as treatment to reduce the risk of copd exacerbations in patients with severe copd associated with chronic bronchitis and a history of exacerbations.

The generics of Daliresp are possible to be released after 08 March, 2024.

Application	Filing Date	Opposition Party	Legal Status
EP10173234A	2014-02-17	Generics [UK] Limited	Revoked
EP10173234A	2014-02-17	Hexal AG	Revoked
EP03704652A	2012-12-20	Hexal AG	Revoked

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8431154	ASTRAZENECA	Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidone as excipient	Feb, 2023 (3 months ago)
US9468598	ASTRAZENECA	Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient	Feb, 2023 (3 months ago)
US8618142	ASTRAZENECA	Process for the preparation of roflumilast	Mar, 2024 (9 months from now)
US8604064	ASTRAZENECA	Process for the preparation of roflumilast	Mar, 2024 (9 months from now)
US8536206	ASTRAZENECA	Process for the preparation of roflumilast	Mar, 2024 (9 months from now)

Do you want to check out DALIRESP patents from before 2022?

Drugs and Companies using ROFLUMILAST ingredient

Market Authorisation Date: 28 February, 2011

Treatment: Treatment to reduce the risk of copd exacerbations in patients with severe copd associated with chronic bronchitis and a history of exacerbations

Dosage: TABLET;ORAL